REFERENCES

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; doi: 10.3322/caac.21660.

2. Morgan GJ, Johnson DC, Weinhold N, et al. Inherited genetic susceptibility to multiple myeloma. Leukemia 2014;28:518-24.

3. Grosbois B, Jego P, Attal M, et al. Familial multiple myeloma: report of fifteen families. Br J Haematol 1999;105:768-70.

4. Hemminki K, Li X, Czene K. Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer 2004;108:109-14.

5. VanValkenburg ME, Pruitt GI, Brill IK, et al. Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features. Cancer Causes Control 2016;27:81-91.

6. Bourguet CC, Grufferman S, Delzell E, Delong ER, Cohen HJ. Multiple myeloma and family history of cancer a case-control study. Cancer 1985;56:2133-9.

7. Eriksson M, Hållberg B. Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study. Cancer Causes Control 1992;3:63-7.

8. Schinasi LH, Brown EE, Camp NJ, et al. Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium. Br J Haematol 2016;175:87-101.

9. Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 2006;118:3095-8.

10. Kristinsson SY, Björkholm M, Goldin LR, et al. Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 2009;125:2147-50.

11. Altieri A, Chen B, Bermejo JL, Castro F, Hemminki K. Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer 2006;42:1661-70.

12. Sud A, Kinnersley B, Houlston RS. Genome-wide association studies of cancer: current insights and future perspectives. Nat Rev Cancer 2017;17:692-704.

13. Mitchell JS, Li N, Weinhold N, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun 2016;7:12050.

14. Weinhold N, Johnson DC, Chubb D, et al. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet 2013;45:522-5.

15. Went M, Sud A, Försti A, et al; PRACTICAL consortium. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun 2018;9:3707.

16. Swaminathan B, Thorleifsson G, Jöud M, et al. Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. Nat Commun 2015;6:7213.

17. Chubb D, Weinhold N, Broderick P, et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet 2013;45:1221-5.

18. Broderick P, Chubb D, Johnson DC, et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet 2011;44:58-61.

19. Halvarsson BM, Wihlborg AK, Ali M, et al. Direct evidence for a polygenic etiology in familial multiple myeloma. Blood Adv 2017;1:619-23.

20. Waller RG, Darlington TM, Wei X, et al. Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. PLoS Genet 2018;14:e1007111.

21. Wei X, Calvo-Vidal MN, Chen S, et al. Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Res 2018;78:2747-59.

22. Pertesi M, Vallée M, Wei X, et al. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. Leukemia 2019;33:2324-30.

23. Thomas A, Camp NJ, Farnham JM, Allen-Brady K, Cannon-Albright LA. Shared genomic segment analysis. Mapping disease predisposition genes in extended pedigrees using SNP genotype assays. Ann Hum Genet 2008;72:279-87.

24. Knight S, Abo RP, Abel HJ, et al. Shared genomic segment analysis: the power to find rare disease variants. Ann Hum Genet 2012;76:500-9.

25. McClellan J, King MC. Genetic heterogeneity in human disease. Cell 2010;141:210-7.

26. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 1995;11:241-7.

27. Hanson HA, Leiser CL, Madsen MJ, et al. Family Study Designs Informed by Tumor Heterogeneity and Multi-Cancer Pleiotropies: The Power of the Utah Population Database. Cancer Epidemiol Biomarkers Prev 2020;29:807-15.

28. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-75.

29. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008;27:6920-9.

30. Xu L, Lin DC, Yin D, Koeffler HP. An emerging role of PARK2 in cancer. J Mol Med (Berl) 2014;92:31-42.

31. Xiong D, Wang Y, Kupert E, et al. A recurrent mutation in PARK2 is associated with familial lung cancer. Am J Hum Genet 2015;96:301-8.